Mallinckrodt buys rights to pain management drug Roxicodone
Signs agreement with Xanodyne Pharmaceuticals
Mallinckrodt, the pharmaceuticals business of US healthcare products company Covidien, has agreed with Xanodyne Pharmaceuticals, based in Newport, Kentucky, to purchase the rights to Roxicodone (oxycodone hydrochloride tablets USP) in 5, 15 and 30mg dosage strengths.
Roxicodone, currently marketed in the US, is an immediate release formulation of oxycodone indicated for the management of moderate to severe pain. Mallinckrodt has acquired all rights to the New Drug Application (NDA) for the medication.
No financial details have been disclosed.
Mark Trudeau, president of Covidien’s pharmaceuticals business, said: ‘We are excited about this agreement as it complements our existing portfolio of opioids and leverages our pain management expertise.’
Mallinckrodt is the largest US supplier of opioid pain medications and among the top 10 generic pharmaceuticals manufacturers in the US, based on prescriptions. Its branded portfolio includes Exalgo (hydromorphone HCl) Extended-Release Tablets (CII) and Pennsaid (diclofenac sodium topical solution) 1.5% w/w. Mallinckrodt is also a leading producer of bulk acetaminophen.
Covidien announced last December that it planned to spin off Mallinckrodt into a stand-alone company, a process that should be completed by the middle of next year.
